TickerTalks
Browse all tickers →
TickerTalks›$ACB
ACACB

Aurora Cannabis Inc.

$ACB·$216M·Drug Manufacturers - Specialty & Generic·Healthcare
$3.68-2.9%YTD-12.1%1Y-27.5%
Mentions · last 7 days
2026-08-08: 0 posts2026-08-09: 2 posts2026-08-10: 2 posts2026-08-11: 165 posts2026-08-12: 53 posts2026-08-13: 30 posts2026-08-14: 18 posts271+30%
Price updated 15h ago·X counts updated 12h ago
ACACB
$ACBAurora Cannabis Inc.
$3.68-2.90%271 posts+30%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ACB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-15

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Curaleaf just launched a hostile takeover bid at a 45% premium — Aurora Cannabis is now a specific M&A binary catalyst.

Aurora Cannabis is a Canadian medical-cannabis producer with EU-GMP-certified cultivation — one of the few licensed producers with international-grade medical certification. Curaleaf just launched an unsolicited takeover bid at a 45% premium, turning it into a specific M&A binary.

Where it stands:

  • The Curaleaf bid is the definitional catalyst: unsolicited takeover at 45% premium over 30-day VWAP, going directly to shareholders after Curaleaf's private buyout proposals in June/July were ignored — matters because Curaleaf needs Aurora's EU-GMP cultivation ahead of Curaleaf's uplisting, creating the cross-border medical-cannabis leader.
  • Aurora's board formed a special committee — standard M&A defense playbook, but combined with the sector-consolidation narrative it likely resolves as a higher bid or friendly negotiation, not outright rejection leaving Aurora standalone.
  • The underlying business is genuinely fragile: Q4 FY26 revenue of $67.6M declined 23% year-over-year with -59% gross margin and -70% operating margin — Aurora needs strategic combination or substantial capital raise, and the Curaleaf bid arriving now is arguably the specific event the balance sheet needs.

The story extends if the special committee negotiates a higher bid (60-75% premium is not out of scale for medical-cannabis consolidation) or accepts. What flips it: Aurora board rejection without a superior alternative, or DOJ allegations (suspicious timing per sentiment) materializing into charges that scuttle the deal.

Agrees with X sentimentAgree with the bullish framing — the Curaleaf 45% premium unsolicited bid is a substantive M&A catalyst, and the strategic logic (Curaleaf international distribution + Aurora EU-GMP cultivation ahead of Curaleaf uplisting) is real. The DOJ allegations timing suspiciously dovetailing with the bid, with two grand juries refusing to indict, is the specific counter-noise the crowd is honestly weighing.

What to watch: The Aurora special committee decision and any counter-bid emergence over the next 4-8 weeks: a higher Curaleaf bid or an Aurora acceptance extends the M&A narrative. An Aurora board rejection without a superior alternative or DOJ allegations materializing into charges is what flips the setup.

On the calendar: 2026-11-04 — Q1 FY27 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment49 posts analyzed · as of 2026-08-14

Aurora Cannabis chatter is dominated by Curaleaf's unsolicited take-over bid for ACB — 45% premium over 30-day VWAP, going directly to shareholders after private buyout proposals in June/July were ignored by ACB's board. Aurora formed a special committee. Sector consolidation narrative combines Curaleaf's international distribution with Aurora's EU-GMP cultivation ahead of Curaleaf uplisting. Some counter-noise about DOJ allegations that dovetail suspiciously with the bid timing (two grand juries refused to indict). Bulls dominate; MSOS-basket rally implied.

Read the AI verdict + X sentiment for $ACB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Canadian cannabis producer selling dried flower, oils, and edibles to medical and adult-use markets across Canada and internationally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $ACB.

Drug Manufacturers - Specialty & Generic · Healthcare

No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+48.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-15.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-29.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-21.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
32.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.05$-0.13+64.6%
Q1 2026Jun 11, 2026$-0.71$-0.07-914.1%
Q4 2025Feb 4, 2026$0.09$0.10-7.4%
Q3 2025Nov 5, 2025$0.09$0.03+200.0%
Next earningsWed, Nov 4·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY27$67.6M-23.4%-5.9%-70.2%$-0.07$-9.9M
Q4 FY26$38.1M-57.9%47.8%-66.1%$-0.99$-5.4M
Q3 FY26$94.2M+6.8%49.5%5.1%$0.03$11.0M
Q2 FY26$90.4M+11.4%35.7%-20.2%$-0.91$-46.7M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$294.8M$291.2M – $298.5M-$0.27-$0.28 – -$0.265
FY28$326.4M$318.4M – $334.7M$0.01$0.01 – $0.013
FY29$372.3M$357.9M – $386.7M$0.29$0.16 – $0.432
FY30$400.3M$390.5M – $410.5M$0.35$0.34 – $0.371
FY31$434.1M$423.4M – $445.1M$0.60$0.58 – $0.621

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.27%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+25.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-0.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 61.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.345-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 22 other (21 6-Ks · 1 40-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Is Acquiring Aurora Cannabis a Good Move for Curaleaf?fool.com·3d agoShould You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?zacks.com·3d agoCuraleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here's What This Means for Investors.fool.com·3d agoAURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BIDgurufocus.com·4d agoAURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC.prnewswire.com·4d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ZYBT$ETON$EMBC$ELAN$RGC$TAK$LNTH$BHC
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport